O'Brien Peter James, Edvardsson Anna
School of Veterinary Medicine, University College Dublin , Stillorgan Road, Belfield, Dublin 4, Ireland.
Advanced Diagnostic Laboratory , Park West Enterprise Centre, Lavery Avenue, Park West, Dublin 12, Ireland.
Chem Res Toxicol. 2017 Mar 20;30(3):804-829. doi: 10.1021/acs.chemrestox.6b00403. Epub 2017 Feb 22.
A multiparametric, live-cell, high-content-screening (HCS) cytotoxicity assay was first demonstrated in 2006 ( Arch. Toxicol. 2006 , 80 , 580 - 604 ) to be highly concordant with human hepatotoxicity, including idiosyncratic hepatotoxicities and other target organ toxicities in contrast to historical assays. The success of the assay was attributed to its simultaneous measurement of multiple appropriate "cytobiomarkers": use of human cells with xenometabolic competence for toxicities mediated by metabolites, 72 h exposure to enable expression of slower-acting toxicants, exposure to a wide-range of concentrations from 30- to 100-fold the efficacious concentration, and normalizing the in vitro cytotoxic concentration to an estimate of the in vivo concentration of exposure. An overwhelming volume of evidence has accumulated over the last 10 years to support this approach as necessary in predictive toxicology. Equivalent assays have now been successfully applied in ∼50 studies across a wide variety of toxicants, toxicities, cell types, and disciplines. Review herein of the wider literature on cytotoxicity since the first assay was reported 100 years ago supports the selection of key cytobiomarkers along a final common pathway of cell injury, including cell proliferation, mitochondrial activity, apoptosis, lysosomal mass, oxidative stress, and cell membrane permeability. HCS studies without inclusion of such key cytobiomarkers or without testing to sufficiently high concentration have not been as successful. Furthermore, a subset of the original toxicants has been reanalyzed herein using the original HCS assay and has confirmed their high sensitivities and specificities across locations, HCS technologies, staff, laboratories, and time. A protocol is demonstrated for operational validation of the assay within laboratories to demonstrate proficiency and quality management.
一种多参数、活细胞、高内涵筛选(HCS)细胞毒性检测方法于2006年首次得到证实(《毒理学文献》,2006年,第80卷,第580 - 604页),与人类肝毒性高度一致,包括特异质性肝毒性和其他靶器官毒性,这与以往的检测方法不同。该检测方法的成功归因于其能同时测量多种合适的“细胞生物标志物”:使用具有异源代谢能力的人类细胞来检测由代谢物介导的毒性,72小时的暴露时间以使作用较慢的毒物得以表达,暴露于有效浓度30至100倍的广泛浓度范围内,并将体外细胞毒性浓度归一化为体内暴露浓度的估计值。在过去10年中积累了大量证据,支持这种方法在预测毒理学中是必要的。等效检测方法现已成功应用于约50项研究,涉及多种毒物、毒性、细胞类型和学科。本文对自100年前首次报道细胞毒性检测方法以来更广泛的文献进行回顾,支持沿着细胞损伤的最终共同途径选择关键细胞生物标志物,包括细胞增殖、线粒体活性、细胞凋亡、溶酶体质量、氧化应激和细胞膜通透性。未纳入此类关键细胞生物标志物或未进行足够高浓度检测的HCS研究并不那么成功。此外,本文使用原始的HCS检测方法对一部分原始毒物进行了重新分析,证实了它们在不同地点、HCS技术、人员、实验室和时间范围内都具有高灵敏度和特异性。本文展示了一种在实验室内对该检测方法进行操作验证的方案,以证明其熟练度和质量管理。